Frankel Commercialization Fund - Portfolio

Overview | Student Participation | Application for Funding | Portfolio | Advisors

Arbor Photonics

Arbor Photonics is an Ann Arbor based company commercializing technology that originated in the U-M's Department of Electrical Engineering and Computer Science (EECS). Ann Arbor-based RPM Ventures, which invests in university spinouts and technology-focused companies that target customers based in the Midwest, led the initial round of financing.

Arbor Photonics and its chief science officer, EECS Professor Almantas Galvanauskas, have developed a novel scalable optical fiber technology that enables high-power fiber lasers to be used in a variety of new materials-processing applications in the automotive, electronics and aerospace industries while offering a lower-cost replacement to existing bulky laser systems. Led by Phillip Amaya, a 20-year veteran of the laser industry, Arbor Photonics intends to use the Frankel seed money for customer identification, prototype development and assembly, and the development of engineering and manufacturing plans for the company. The company possesses a stellar team built around a disruptive, proprietary technology that meets a clear market need.

"We're very fortunate to find both the technological and financial seeds for our business at the University of Michigan," Amaya said upon closing the investment in December, 2007. "The Frankel Fund's early-stage investment plays a critical role in helping us transform the technology into a product demonstration and the business concept into a competitive strategy. The Frankel students are an impressive team to work with and we're looking forward to their continued participation in Arbor Photonics."

The Frankel Fund has visiting rights to the Arbor Photonics Board Meetings and works closely with the company to provide whatever assistance it can to the management team.

BeholzTech

BeholzTech Inc., was founded in Flint, Mich., by Lars Beholz, a visiting associate professor of chemistry at Kettering University. BeholzTech's technology effectively coats polyolefin plastics, making them easier to modify and adhere to other materials. Polyolefins are tiny plastic pellets that are used to make thousands of products we use everyday.

Prior to Beholz's innovation, the coating, bonding and chemical modification of polyolefin plastics was generally prohibitive due to the significant financial investment required and the potentially dangerous chemical byproducts created. BeholzTech's safer, cheaper and more effective technology to treat polyolefin plastics will enable the further use of polyolefins by the $110 billion plastics industry.

"We are really pleased to have been able to partner with the Frankel Fund," Beholz said at the time of the investment closing. "The money provided will be absolutely critical to enable BeholzTech to produce sample products with which to begin discussions with potential customers and future investors. Working with the Frankel Fund has been a great learning experience as I navigate the company through its startup phase."

BeholzTech intends to use the seed money for prototype development, customer identification, marketing plan development and the recruitment of key management personnel.

Surgimatix

Surgimatix is a Chicago-based company founded by Dr. Jafar Hasan, a surgeon from the University of Michigan Hospital. Hasan, who recently completed his plastic surgery residency, is a graduate of U-M's joint MD/MBA program.

The Company has developed an innovative wound-closure device that combines the convenience of a surgical stapler with the aesthetic and closure strength benefits of manual sutures. This novel approach decreases the time of surgery, which saves operation costs and reduces scarring for patients.

Surgimatix intends to utilize the Frankel Fund seed money to fund pre-clinical testing, refine the clinical scale prototype design, and develop the resorbable fastener for the device. The Frankel Fund was formed to help accelerate commercialization of technology and the formation of companies at the U-M.

“We are excited about the opportunity to invest in a company founded by Dr. Hasan,” said Philip Kowalczyk, a member of the Frankel Fund’s Health Care Team. “We believe that the Surgimatix technology demonstrates his unique understanding of the need for a better suturing approach in combination with his business acumen.”

While studying for his MBA, Hasan was a member of the initial Frankel Fund team in 2006. “Working on the Frankel Fund provided me with hands-on experience in the areas of due diligence and commercialization,” stated Hasan. “As an entrepreneur, the Frankel Fund will be instrumental in helping us to move from an idea that demonstrates a health care breakthrough to a marketable product that could dramatically improve surgical recovery.”

The Frankel Fund has visiting rights to the Surgimatix Board Meetings.